Brian M. Wolpin

30.1k total citations · 2 hit papers
180 papers, 7.3k citations indexed

About

Brian M. Wolpin is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Brian M. Wolpin has authored 180 papers receiving a total of 7.3k indexed citations (citations by other indexed papers that have themselves been cited), including 126 papers in Oncology, 58 papers in Cancer Research and 40 papers in Molecular Biology. Recurrent topics in Brian M. Wolpin's work include Pancreatic and Hepatic Oncology Research (84 papers), Cancer Genomics and Diagnostics (40 papers) and Colorectal Cancer Treatments and Studies (24 papers). Brian M. Wolpin is often cited by papers focused on Pancreatic and Hepatic Oncology Research (84 papers), Cancer Genomics and Diagnostics (40 papers) and Colorectal Cancer Treatments and Studies (24 papers). Brian M. Wolpin collaborates with scholars based in United States, Canada and United Kingdom. Brian M. Wolpin's co-authors include Charles S. Fuchs, Robert J. Mayer, Jeffrey A. Meyerhardt, Edward L. Giovannucci, Peter Kraft, Kimmie Ng, Harvey J. Mamon, Jennifer A. Chan, JoAnn E. Manson and Shuji Ogino and has published in prestigious journals such as Nature, Science and New England Journal of Medicine.

In The Last Decade

Brian M. Wolpin

177 papers receiving 7.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Tissue of origin dictates branched-chain amino acid metabolism in mutantKras-driven cancers

2016 438 citations Jared R. Mayers, Margaret E. Torrence et al. profile →
Efficacy of Preoperative mFOLFIRINOX vs mFOLFIRINOX Plus Hypofractionated Radiotherapy for Borderline Resectable Adenocarcinoma of the Pancreas

2022 144 citations Matthew H. G. Katz, Brian M. Wolpin et al. profile →

Peers

Countries citing papers authored by Brian M. Wolpin

Since Specialization

Citations

This map shows the geographic impact of Brian M. Wolpin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brian M. Wolpin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brian M. Wolpin more than expected).

Fields of papers citing papers by Brian M. Wolpin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Brian M. Wolpin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brian M. Wolpin. The network helps show where Brian M. Wolpin may publish in the future.

Co-authorship network of co-authors of Brian M. Wolpin

This figure shows the co-authorship network connecting the top 25 collaborators of Brian M. Wolpin. A scholar is included among the top collaborators of Brian M. Wolpin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brian M. Wolpin. Brian M. Wolpin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Identifying regulators of aberrant stem cell and differentiation activity in colorectal cancer using a dual endogenous reporter system 2024 ·Nature Communications ·Sándor Spisák, David J. Chen, (unknown), (unknown), Zhixin Li, (unknown), Laura Vízkeleti, Viktória Tisza, Pushpamali De Silva, Marios Giannakis, Brian M. Wolpin, Jun Qi, Nilay S. Sethi	5
2	Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01. 2024 ·Journal of Clinical Oncology ·Jennifer J. Knox, Elizabeth M. Jaffee, Grainne M. O’Kane, Daniel A. King, Dan Laheru, Kenneth H. Yu, Kimberly Perez, Amber N. Habowski, Robert C. Grant, Sandra E. Fischer, Andrew J. Aguirre, Raymond Woo-Jun Jang, Craig Devoe, Eileen M. O’Reilly, Anna Dodd, Brian M. Wolpin, Xiang Y. Ye, Faiyaz Notta, Steven Gallinger, David A. Tuveson	6
3	Machine Learning Links T-cell Function and Spatial Localization to Neoadjuvant Immunotherapy and Clinical Outcome in Pancreatic Cancer 2024 ·Cancer Immunology Research ·Katie E. Blise, Shamilene Sivagnanam, Courtney B. Betts, (unknown), Nell Kirchberger, (unknown), Emma E. Furth, Andressa Dias Costa, Jonathan A. Nowak, Brian M. Wolpin, Robert H. Vonderheide, Jeremy Goecks, Lisa M. Coussens, Katelyn T. Byrne	10
4	652O Preliminary clinical activity of RMC-6236, a first-in-class, RAS-selective, tri-complex RAS-MULTI(ON) inhibitor in patients with KRAS mutant pancreatic ductal adenocarcinoma (PDAC) and non-small cell lung cancer (NSCLC) 2023 ·Annals of Oncology ·Kathryn C. Arbour, Salman R. Punekar, Ignacio Garrido‐Laguna, David S. Hong, Brian M. Wolpin, (unknown), (unknown), Alexander Starodub, (unknown), Sam S. Chang, (unknown), Zeena Salman, (unknown), Corinne E. Gustafson, Alexander I. Spira	70
5	Relationship between ABO Blood Group Alleles and Pancreatic Cancer Is Modulated by Secretor ( FUT2 ) Genotype, but Not Lewis Antigen ( FUT3 ) Genotype 2023 ·Cancer Epidemiology Biomarkers & Prevention ·Jihye Kim, Chen Yuan, Laufey T. Ámundadóttir, Brian M. Wolpin, Alison P. Klein, Harvey A. Risch, Peter Kraft	6
6	Multicenter randomized controlled trial of neoadjuvant chemoradiotherapy alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic adenocarcinoma 2023 ·Journal for ImmunoTherapy of Cancer ·Matthew H. G. Katz, Gina R. Petroni, Todd W. Bauer, Matthew J. Reilley, Brian M. Wolpin, (unknown), Tanios Bekaii‐Saab, Rawad Elias, Nipun B. Merchant, Andressa Dias Costa, Patrick J. Lenehan, Victoire Cardot‐Ruffino, Scott J. Rodig, Kathleen L. Pfaff, Stephanie K. Dougan, Jonathan A. Nowak, Gauri R. Varadhachary, Craig L. Slingluff, Osama E. Rahma	18
7	Retrospective Case Series Analysis ofRAFFamily Alterations in Pancreatic Cancer: Real-World Outcomes From Targeted and Standard Therapies 2021 ·JCO Precision Oncology ·Andrew Hendifar, Edik M. Blais, Brian M. Wolpin, Vivek Subbiah, Eric A. Collisson, (unknown), Timothy Lewis Cannon, Kenna Shaw, Emanuel F. Petricoin, Samuel J. Klempner, Emily E. Lyons, Andrea Wang‐Gillam, Michael J. Pishvaian, Eileen M. O’Reilly	22
8	The oral microbiome in relation to pancreatic cancer risk in African Americans 2021 ·British Journal of Cancer ·Jessica L. Petrick, Jeremy E. Wilkinson, Dominique S. Michaud, Qiuyin Cai, Hanna Gerlovin, Lisa B. Signorello, Brian M. Wolpin, Edward Ruiz-Narváez, Jirong Long, Yaohua Yang, W. Evan Johnson, Xiao‐Ou Shu, Curtis Huttenhower, Julie R. Palmer	21
9	Population-Scale CT-based Body Composition Analysis of a Large Outpatient Population Using Deep Learning to Derive Age-, Sex-, and Race-specific Reference Curves 2020 ·Radiology ·Kirti Magudia, Christopher P. Bridge, Camden Bay, Ana Babić, Florian J. Fintelmann, Fabian M. Troschel, Nityanand Miskin, (unknown), Lauren K. Brais, Katherine P. Andriole, Brian M. Wolpin, Michael H. Rosenthal	98
10	Genetic and Circulating Biomarker Data Improve Risk Prediction for Pancreatic Cancer in the General Population 2020 ·Cancer Epidemiology Biomarkers & Prevention ·Jihye Kim, Chen Yuan, Ana Babić, Ying Bao, Clary B. Clish, Michaël Pollak, Laufey T. Ámundadóttir, Alison P. Klein, Rachael Z. Stolzenberg‐Solomon, Pari V. Pandharipande, Lauren K. Brais, Marisa W. Welch, Kimmie Ng, Edward L. Giovannucci, Howard D. Sesso, JoAnn E. Manson, Meir J. Stampfer, Charles S. Fuchs, Brian M. Wolpin, Peter Kraft	17
11	iRGD-guided Tumor-penetrating Nanocomplexes for Therapeutic siRNA Delivery to Pancreatic Cancer 2018 ·Molecular Cancer Therapeutics ·Justin H. Lo, Liangliang Hao, Mandar D. Muzumdar, Srivatsan Raghavan, Ester J. Kwon, Emilia M. Pulver, (unknown), Andrew J. Aguirre, Brian M. Wolpin, Charles S. Fuchs, William C. Hahn, Tyler Jacks, Sangeeta N. Bhatia	65
12	Impact of Pre-analytic Blood Sample Collection Factors on Metabolomics 2016 ·Cancer Epidemiology Biomarkers & Prevention ·Mary K. Townsend, Ying Bao, Elizabeth M. Poole, Kimberly A. Bertrand, Peter Kraft, Brian M. Wolpin, Clary B. Clish, Shelley S. Tworoger	41
13	Association of Common Susceptibility Variants of Pancreatic Cancer in Higher-Risk Patients: A PACGENE Study 2016 ·Cancer Epidemiology Biomarkers & Prevention ·Erica J. Childs, Kari G. Chaffee, Steven Gallinger, Sapna Syngal, Ann G. Schwartz, Michele L. Coté, Melissa L. Bondy, Ralph H. Hruban, Stephen J. Chanock, Robert N. Hoover, Charles S. Fuchs, David N. Rider, Laufey T. Ámundadóttir, Rachael Z. Stolzenberg‐Solomon, Brian M. Wolpin, Harvey A. Risch, Michael Goggins, Gloria M. Petersen, Alison P. Klein	22
14	Tissue of origin dictates branched-chain amino acid metabolism in mutant Kras-driven cancers 2016 ·PMC ·Jared R. Mayers, Margaret E. Torrence, Laura V. Danai, Thales Papagiannakopoulos, (unknown), (unknown), Allison N. Lau, Bing Ji, (unknown), Aaron M. Hosios, Alexander Muir, Christopher R. Chin, Elizaveta Freinkman, Tyler Jacks, Brian M. Wolpin, Dennis Vitkup, Matthew G. Vander Heiden	34
15	Cumulative consumption of branched-chain amino acids and incidence of type 2 diabetes 2016 ·International Journal of Epidemiology ·Yan Zheng, Yanping Li, Qibin Qi, Adela Hruby, JoAnn E. Manson, Walter C. Willett, Brian M. Wolpin, Frank B. Hu, Lu Qi	126
16	Phase II and Pharmacodynamic Study of Autophagy Inhibition Using Hydroxychloroquine in Patients With Metastatic Pancreatic Adenocarcinoma 2014 ·The Oncologist ·Brian M. Wolpin, Douglas A. Rubinson, Xiaoxu Wang, Jennifer A. Chan, James M. Cleary, Peter C. Enzinger, Charles S. Fuchs, Nadine J. McCleary, Jeffrey A. Meyerhardt, Kimmie Ng, Deborah Schrag, (unknown), Beverly Spicer, (unknown), Harvey J. Mamon, Alec C. Kimmelman	289
17	Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer 2013 ·The Oncologist ·Brian M. Wolpin, Kimmie Ng, Andrew X. Zhu, Thomas A. Abrams, Peter C. Enzinger, Nadine J. McCleary, Deborah Schrag, Eunice L. Kwak, Jill N. Allen, Pankaj Bhargava, Jennifer A. Chan, Wolfram Goessling, Lawrence S. Blaszkowsky, Jeffrey G. Supko, (unknown), Kaori Sato, Eileen Regan, Jeffrey A. Meyerhardt, Charles S. Fuchs	38
18	Molecular pathological epidemiology of epigenetics: emerging integrative science to analyze environment, host, and disease 2013 ·Modern Pathology ·Shuji Ogino, Paul Lochhead, Andrew T. Chan, Reiko Nishihara, Eunyoung Cho, Brian M. Wolpin, Jeffrey A. Meyerhardt, Alexander Meissner, Eva Schernhammer, Charles S. Fuchs, Edward L. Giovannucci	166
19	ABO Blood Group and Risk of Coronary Heart Disease in Two Prospective Cohort Studies 2012 ·Arteriosclerosis Thrombosis and Vascular Biology ·Meian He, Brian M. Wolpin, Kathryn M. Rexrode, JoAnn E. Manson, Eric B. Rimm, Frank B. Hu, Lu Qi	151
20	Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer 2009 ·British Journal of Cancer ·Kimmie Ng, Brian M. Wolpin, Jeffrey A. Meyerhardt, Kana Wu, Andrew T. Chan, Bruce W. Hollis, Edward L. Giovannucci, Meir J. Stampfer, W. C. Willett, Charles S. Fuchs	105

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact